Vertex Says Phase 3 RAINIER Trial Meets Primary Endpoint in IgAN
Povatacicept cut proteinuria 49.8% versus placebo at Week 36 (P<0.0001) and met both secondary endpoints. Vertex’s FDA BLA for accelerated approval is under review, with a Nov. 30, 2026 PDUFA date.